BioSpace News Archive

KemPharm, Inc. today announced that it has been named the 2021 David J. Gury Company of the Year by BioFlorida.

Todos Medical, Ltd. today announced the Company has entered into a new agreement with holders of its convertible notes that provides for a 90-day moratorium on conversion of those convertible notes and a restriction on sales of common shares owned by those noteholders (collectively the “New Lockup”).

Clinical Enterprise, Inc., a Eurofins Scientific Company, today announced it has launched a new partnership with Ginkgo Bioworks (NYSE: DNA) to support Operation Expanded Testing Program with the U.S. Department of Health and Human Services and Department of Defense.

Optinose today announced its Board of Directors has named Drs. Eric Bednarski and Kyle Dempsey as new directors.

Attralus, Inc. today announced encouraging new preclinical data for AT-03, the company’s first-in-class pan-amyloid removal (PAR) therapeutic being developed for the treatment of systemic amyloidosis.

Iterum Therapeutics plc today announced the appointment of Sailaja Puttagunta, M.D., to the newly created position of Chief Medical Officer, where she will oversee global clinical evelopment and regulatory initiatives for Iterum.

Aquestive Therapeutics, Inc. today reported that it has received a written response from FDA to its pre-investigational new drug (pre-IND) meeting submission confirming that the development of AQST-109 for the treatment of anaphylaxis under the 505(b)(2) pathway is acceptable.

Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the feature release of Pinnacle 21 Enterprise 5.1.0, which updates the Company’s flagship software for preparing clinical trial data for biosimulation and regulatory submission.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), today presents new positive efficacy data from its ongoing Phase IIa ALICE trial, investigating iadademstat in combination with azacitidine in elderly or unfit patients with acute myeloid leukemia (AML), at the 63rd American Society of Hematology Annual Conference, ASH-2021.

Galderma announced today the new label for SCULPTRA® (injectable poly-L-lactic acid (PLLA)), the first and only FDA-approved PLLA facial injectable treatment that helps stimulate the skin’s own collagen production, to smooth facial wrinkles, such as smile lines.